“We saw that the cancer cells responded to the nearby blood vessel, moved rapidly towards it and invaded it, which is the first step in tumour spread,” said Pierfrancesco Pagella, senior associate professor at Linköping University, describing results published in PNAS.
His team has built an organ-on-chip model of head and neck cancer small enough to fit on a postage stamp.
The chip, developed at Linköping University in Sweden with MiMic Lab at Politecnico di Milano, hosts living tumour cells, blood vessels and nerves grown from stem cells on a plate roughly the size of a stamp. It lets researchers watch, under controlled conditions, how a solid tumour interacts with the tissue around it — something animal models and cell cultures cannot show in the same way.
Why it matters: a tumour is not just cancer cells. It grows in intimate contact with blood vessels, nerves and the surrounding protein web, and those neighbours shape how it spreads, causes pain and resists drugs.
Pagella put it plainly: “Rather than having to carry out research on animals or test potential drugs in humans, we want to be able to carry out tests in a single microsystem in the laboratory.”
In Plain English: The Clinical Takeaway
- Scientists can now grow a mini head-and-neck tumour — with its own blood vessels and nerves — on a chip the size of a stamp, and watch it behave in real time.
- The material surrounding the tumour changed how cancer cells moved and how well the chemotherapy drug cisplatin killed them.
- Tumours touching nerves grew larger but were less likely to invade blood vessels — nerves are not just bystanders in cancer.
- This is lab research, not a new treatment; no patient-facing therapy exists yet from this work.
A tumour’s neighbourhood changed its behaviour
The team built the model in stages. First they recreated the extracellular matrix — the body’s natural scaffold of proteins and carbohydrates — using hyaluronic acid, collagen and laminins. The cancer cells behaved very differently depending on that surrounding material.

Next came blood vessels. The cells migrated rapidly toward the vessel and invaded it, the first step in tumour spread, but their behaviour shifted with the matrix around them. When the researchers pumped cisplatin — a platinum-based chemotherapy commonly used for head and neck cancer — through the vessel structure, the surrounding material again changed how effectively the drug killed the cancer cells.
Finally, the team used stem cells to recreate trigeminal ganglia, the nerve clusters behind sensation and pain in the mouth and face. Within days, nerves had grown around the tumours. “In our three-dimensional system, we saw that tumours in contact with nerves were less likely to invade blood vessels, but at the same time grew larger,” Pagella said.
This result matters especially for head and neck cancer, a disease in which nerves play a dual role — influencing how tumours behave and how aggressive they become, while also being tied to cancer-related pain. Perineural invasion — cancer spreading along nerves — is a recognised feature of this disease, and a chip that reproduces tumour–nerve contact gives researchers a way to study it directly rather than inferring it from tissue samples.
Why head and neck cancer needs a better model
Head and neck cancers arise in the mouth, throat, larynx, nose and sinuses, and treatment often involves surgery, radiotherapy and platinum-based chemotherapy such as cisplatin. Studying these tumours in animals is slow, expensive and imperfect; studying them in flat cell dishes strips away the three-dimensional neighbourhood that drives their behaviour. The organ-on-chip approach — microfluidic devices that recreate organ-level function outside the body — aims to close that gap.
“If we want to understand why a tumour grows, spreads, causes pain or resists treatment, we need models that can replicate the interactions between the tumour and its surroundings,” Pagella said. The technology was developed with Professor Marco Rasponi’s MiMic Lab at Politecnico di Milano; Rasponi chairs the European Organ-on-Chip Society.
Where the outlets differ — and what comes next
The three reports cover the same study but frame it differently. Healthcare-in-europe.com emphasised the drug-screening angle: the researchers believe the model could eventually prove useful for drug screening and testing treatment response, and could be adapted to other solid tumour types where interactions with surrounding structures matter.
Medical Xpress highlighted the replacement of animal and human testing with a single microsystem. Tomorrow’s World Today focused on the construction sequence — matrix, vessels, nerves — that made the findings possible.
What none of the reports provide is a timeline for clinical use. The model is a research tool, demonstrated as a working concept; adaptation to other tumour types and routine drug testing remain future applications, and no regulatory pathway with the FDA or EMA has been described for this specific system.
Organ-on-chip devices more broadly are under active regulatory discussion on both sides of the Atlantic as potential complements to animal studies, but this study does not change that status.
Backing for the work came from sources including the Swedish Research Council, the Knut and Alice Wallenberg Foundation, the European Research Council (ERC) and the Swedish Foundation for Strategic Research (SSF) — funders from the public and charitable sectors rather than drug manufacturers, which limits commercial framing of the results. The study was published in PNAS.
| Element on the chip | What it is | What the researchers observed |
|---|---|---|
| Extracellular matrix | Hydrogel of hyaluronic acid, collagen and laminins | Changed how cancer cells moved and responded to cisplatin |
| Blood vessel | Microfluidic vessel structure carrying chemotherapy | Cancer cells migrated toward and invaded it — the first step in spread |
| Trigeminal ganglia | Nerves grown from stem cells, tied to facial sensation and pain | Nerves grew around tumours within days; tumours grew larger but invaded vessels less |
Contraindications & When to Consult a Doctor
Patients undergoing cisplatin treatment should not alter their regimen based on these findings; the chip's observation that surrounding tissue affects cisplatin sensitivity is a research result, not evidence for or against any individual's treatment plan.
Anyone with head or neck cancer should discuss drug choices, side effects and pain management with their oncology team. Persistent mouth or facial pain, unexplained lumps, difficulty swallowing or voice changes warrant prompt medical assessment regardless of research developments. Reader-facing guidance on symptoms and treatment belongs with qualified clinicians and national cancer services, not with an early-stage laboratory model.
The takeaway
The model’s value, as the researchers see it, is what it makes visible: nerves as an active component of the tumour microenvironment, and matrix composition as a variable that shapes both invasion and drug response.
Those are mechanisms that flat cultures hide and animal studies blur. The next test is whether the concept transfers to other solid tumours and, eventually, whether drug screening on chips predicts what happens in patients — a question this study raises but does not answer.
As Pagella’s team put it in their published work, the model enables the study of nerves as an active part of the tumour’s surroundings — “particularly interesting in head and neck cancer, where nerves are involved both in regulating tumour behaviour and aggressiveness, and in cancer-related pain.”
References
- Pagella, P. et al., Proceedings of the National Academy of Sciences (PNAS) — https://www.pnas.org/doi/10.1073/pnas.2602541123
- Healthcare-in-Europe, “Organ-on-chip shows how head and neck cancer interacts with its surroundings”
- Medical Xpress, “Organ-on-chip shows how tumors interact with nerves and blood vessels”
- Tomorrow’s World Today, “Organ-On-Chip Reveals How Cancer Interacts with Surroundings”
- Linköping University press material